InsidersTradesSigma
Total declarations
Companies
▲ Purchases (15 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
15
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-49.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Muralidhar Bali, Director. Officer active across 2 companies, notably Reneo Pharmaceuticals, Inc.. In total, 15 filings have been logged. Breakdown: 15 buys · 0 sell. Total volume traded: €3.2m. History available since 26 May 2021. The latest transaction was filed on 19 May 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
1,472,126 shares@ US$0.19370.78% mcap100.0% of flowCommon StockSEC:0001209191-22-030549:0
Ideal exit: 13 Feb 2023 (T+270)
111,736 shares@ US$8.5027.1% of flowCommon StockSEC:0001209191-21-046803
Ideal exit: 10 Apr 2022 (T+270)
111,736 shares@ US$8.5027.1% of flowCommon StockSEC:0001209191-21-046803:0
Ideal exit: 10 Apr 2022 (T+270)
20,710 shares@ US$9.28275.4% of flowCommon StockSEC:0000905718-21-000834
Ideal exit: 20 Mar 2022 (T+270)
20,710 shares@ US$9.28275.4% of flowCommon StockSEC:0000905718-21-000834:0
Ideal exit: 20 Mar 2022 (T+270)
32,659 shares@ US$9.03058.4% of flowCommon StockSEC:0000905718-21-000816
Ideal exit: 18 Mar 2022 (T+270)
32,659 shares@ US$9.03058.4% of flowCommon StockSEC:0000905718-21-000816:0
Ideal exit: 18 Mar 2022 (T+270)
16,605 shares@ US$9.49774.4% of flowCommon StockSEC:0000905718-21-000770:0
Ideal exit: 5 Mar 2022 (T+270)
16,605 shares@ US$9.49774.4% of flowCommon StockSEC:0000905718-21-000770
Ideal exit: 5 Mar 2022 (T+270)
12,100 shares@ US$9.25153.1% of flowCommon StockSEC:0000905718-21-000760
Ideal exit: 28 Feb 2022 (T+270)
12,100 shares@ US$9.25153.1% of flowCommon StockSEC:0000905718-21-000760:0
Ideal exit: 28 Feb 2022 (T+270)
14 shares@ US$9.500.0% of flowCommon StockSEC:0000905718-21-000744
Ideal exit: 22 Feb 2022 (T+270)
14 shares@ US$9.500.0% of flowCommon StockSEC:0000905718-21-000744:0
Ideal exit: 22 Feb 2022 (T+270)
5,915 shares@ US$9.38211.5% of flowCommon StockSEC:0000905718-21-000738:0
Ideal exit: 20 Feb 2022 (T+270)
5,915 shares@ US$9.38211.5% of flowCommon StockSEC:0000905718-21-000738
Ideal exit: 20 Feb 2022 (T+270)
15 of 15 declarations
About Muralidhar Bali
Muralidhar Bali is an executive at Reneo Pharmaceuticals, Inc.
